Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus TQB2450 in EGFR-mutant NSCLC after EGFR TKI failure
ChiCTR1900026273Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Oct 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and benmelstobart in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Progression-free survival and Maximum tolerated dose. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900026273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026273.